Semaglutide is a pure GLP-1 receptor ligand; tirzepatide adds GIP receptor cross-activity. A structural and in-vitro pharmacology comparison for New Zealand research laboratories.
Semaglutide vs tirzepatide is one of the most-referenced comparisons in incretin-receptor research. Both are synthetic peptides with fatty-acid diacid linkers studied for albumin association, but they are mechanistically distinct research ligands: semaglutide is a GLP-1 receptor mono-agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist. This reference summarises the structural and in-vitro pharmacology differences for a New Zealand research lab selecting between the two.
Semaglutide vs tirzepatide: quick reference table
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Receptors studied | GLP-1 only | GIP + GLP-1 |
| Length | 31 residues | 39 residues |
| Average mass | ~4113.6 Da | ~4813.5 Da |
| Backbone origin | GLP-1(7-37) analog | GIP-derived, GLP-1 cross-reactive |
| Albumin-binding linker | C18 diacid at Lys26 | C20 diacid at Lys20 |
Receptor pharmacology differences
- Semaglutide is studied as a selective GLP-1 receptor agonist in cAMP-reporter assays, with no meaningful cross-activity reported at GIP or glucagon receptors.
- Tirzepatide is studied as a dual agonist, activating both GIP and GLP-1 receptors in parallel reporter-assay panels.
- Both use Aib-type backbone substitutions studied for DPP-4 resistance in plasma-stability assays.
- Both use fatty-acid diacid conjugation strategies studied for reversible serum-albumin association.
In-vitro assay comparison
| Assay focus | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor panel studied | GLP-1R only | GIP-R + GLP-1R |
| Reporter assay type | cAMP accumulation (GLP-1R line) | Parallel cAMP reporter panel |
| Plasma stability studies | Serum incubation + LC-MS | Serum incubation + LC-MS |
| DPP-4 resistance studies | Enzymatic digestion assay | Enzymatic digestion assay |
Which peptide has deeper published in-vitro characterisation?
Semaglutide has the longer publication history as a GLP-1 receptor reference ligand, making it a common comparator compound in incretin-receptor screening panels. Tirzepatide is more recently characterised but is now widely used where researchers specifically need a dual-receptor reference ligand.
Analytical documentation expectations
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
Sourcing research-grade semaglutide and tirzepatide in New Zealand
Kiwi Peps supplies both semaglutide and tirzepatide verified to the KP-99 Purity Standard (99%+ HPLC-MS), tracked through The Batch Book, with Bench-Ready Dispatch nationwide. Strictly for in-vitro research use only.
Frequently asked questions
What is the mechanistic difference between semaglutide and tirzepatide?
Semaglutide is studied as a selective GLP-1 receptor agonist. Tirzepatide is studied as a dual agonist engaging both GIP and GLP-1 receptors.
How do the molecular weights compare?
Semaglutide has an average mass of approximately 4113.6 Da; tirzepatide is approximately 4813.5 Da.
Can semaglutide and tirzepatide be used interchangeably in receptor assays?
No. Because they engage different receptor panels, the choice of ligand should match the receptor system under study.
How does Kiwi Peps verify purity for both peptides?
Every batch is tested to the KP-99 Purity Standard (99%+ HPLC-MS) with results published in The Batch Book.
